| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Chuanchuan Zhou, Haitao Zeng, Xingxing Xiao, Li Wang, Lei Jia, Yanan Shi, Minfang Zhang, Cong Fang, Yanyan Zeng, Taibao Wu, Jiana Huang, Xiaoyan Lian. Global crotonylome identifies EP300-regulated ANXA2 crotonylation in cumulus cells as a regulator of oocyte maturation. International journal of biological macromolecules. 2024-01-04. PMID:38176486. |
crotonylation of anxa2 enhanced the anxa2-egfr binding, and then activated the egfr pathway to affect cumulus cell proliferation and apoptosis. |
2024-01-04 |
2024-01-07 |
mouse |
| Ting Yang, Sijuan Tian, Juan Zhao, Meili Pei, Minyi Zhao, Xiaofeng Yan. LncRNA ABHD11-AS1 activates EGFR signaling to promote cervical cancer progression by preventing FUS-mediated degradation of ABHD11 mRNA. Cell cycle (Georgetown, Tex.). 2023-12-26. PMID:38146687. |
knockdown of abhd11-as1 and egfr significantly inhibited the proliferation, migration, and invasion and promoted apoptosis of siha and hela cells by up-regulating p21 and bax and down-regulating cyclin d1, bcl2, mmp9, and vimentin. |
2023-12-26 |
2023-12-28 |
Not clear |
| Xuxiu Lu, Rilei Yu, Zhen Li, Mengke Yang, Jiajia Dai, Ming Li. JC-010a, a novel selective SHP2 allosteric inhibitor, overcomes RTK/non-RTK-mediated drug resistance in multiple oncogene-addicted cancers. Cancer letters. 2023-12-15. PMID:38101609. |
importantly, jc-010a abolished acquired resistance induced by targeted therapies: in kras-mutant cancers, jc-010a abrogated selumetinib-induced adaptive resistance mediated by rtk/shp2; in bcr-abl-driven leukemia cells, we demonstrated jc-010a inhibited bcr-abl t315i mutation-mediated imatinib resistance and proposed a novel mechanism of jc-010a involving the disrupted co-interaction of shp2, bcr-abl, and hsp90; in non-small cell lung cancer (nsclc) cells, jc-010a inhibited both egfr t790m/c797s mutation and alternate rtk-driven resistance to gefitinib or osimertinib; importantly, we first proposed a novel potential therapeutic strategy for ret-rearranged cancer, we confirmed that jc-010a monotherapy inhibited cell resistance to blu-667, and jc-010a/blu-667 combination prolonged anticancer response both in vivo and in vitro cancer models by inhibiting the alternate met activation-induced ras/mapk reactivation, thereby promoting cancer cell apoptosis. |
2023-12-15 |
2023-12-18 |
Not clear |
| Momoko Gyoten, Yi Luo, Rina Fujiwara-Tani, Shiori Mori, Ruiko Ogata, Shingo Kishi, Hiroki Kuniyas. Lovastatin Treatment Inducing Apoptosis in Human Pancreatic Cancer Cells by Inhibiting Cholesterol Rafts in Plasma Membrane and Mitochondria. International journal of molecular sciences. vol 24. issue 23. 2023-12-09. PMID:38069135. |
in the three gem-resistant cell lines derived from mia and panc1, the lipid rafts in the cell membrane and the mitochondria were increased to activate egfr and akt and to increase bcl2-bax binding, which suppressed apoptosis. |
2023-12-09 |
2023-12-17 |
human |
| Syam Mohan, Mohammed Ageeli Hakami, Hamad Ghaleb Dailah, Asaad Khalid, Asim Najmi, Khalid Zoghebi, Maryam A Halaw. The emerging role of noncoding RNAs in the EGFR signaling pathway in lung cancer. Pathology, research and practice. vol 253. 2023-12-09. PMID:38070221. |
micrornas, as versatile post-transcriptional regulators, have been shown to target various components of the egfr pathway, influencing cancer cell proliferation, migration, and apoptosis. |
2023-12-09 |
2023-12-17 |
Not clear |
| Ibrahim H Eissa, Reda G Yousef, Eslam B Elkaeed, Aisha A Alsfouk, Dalal Z Husein, Ibrahim M Ibrahim, Hesham A El-Mahdy, Hazem Elkady, Ahmed M Metwal. Computer-Assisted Drug Discovery of a Novel Theobromine Derivative as an EGFR Protein-Targeted Apoptosis Inducer. Evolutionary bioinformatics online. vol 19. 2023-12-04. PMID:38046652. |
computer-assisted drug discovery of a novel theobromine derivative as an egfr protein-targeted apoptosis inducer. |
2023-12-04 |
2023-12-10 |
Not clear |
| Ibrahim H Eissa, Reda G Yousef, Eslam B Elkaeed, Aisha A Alsfouk, Dalal Z Husein, Ibrahim M Ibrahim, Hesham A El-Mahdy, Hazem Elkady, Ahmed M Metwal. Computer-Assisted Drug Discovery of a Novel Theobromine Derivative as an EGFR Protein-Targeted Apoptosis Inducer. Evolutionary bioinformatics online. vol 19. 2023-12-04. PMID:38046652. |
the overexpression of the epidermal growth factor receptor (egfr) marks it as a pivotal target in cancer treatment, with the aim of reducing its proliferation and inducing apoptosis. |
2023-12-04 |
2023-12-10 |
Not clear |
| Wael A A Fadaly, Taha H Zidan, Nesma M Kahk, Fatma E A Mohamed, Marwa M Abdelhakeem, Rehab G Khalil, Mohamed T M Nem. New pyrazolyl-thiazolidinone/thiazole derivatives as celecoxib/dasatinib analogues with selective COX-2, HER-2 and EGFR inhibitory effects: design, synthesis, anti-inflammatory/anti-proliferative activities, apoptosis, molecular modelling and ADME studies. Journal of enzyme inhibition and medicinal chemistry. vol 38. issue 1. 2023-11-27. PMID:38010912. |
new pyrazolyl-thiazolidinone/thiazole derivatives as celecoxib/dasatinib analogues with selective cox-2, her-2 and egfr inhibitory effects: design, synthesis, anti-inflammatory/anti-proliferative activities, apoptosis, molecular modelling and adme studies. |
2023-11-27 |
2023-11-29 |
Not clear |
| Dujuan Li, Lifei Lian, Lei Huang, Marcin Gamdzyk, Yi Huang, Desislava Doycheva, Gaigai Li, Shufeng Yu, Yong Guo, Ruiqing Kang, Hong Tang, Jiping Tang, Lingfei Kong, John H Zhan. Delayed recanalization reduced neuronal apoptosis and neurological deficits by enhancing liver-derived trefoil factor 3-mediated neuroprotection via LINGO2/EGFR/Src signaling pathway after middle cerebral artery occlusion in rats. Experimental neurology. 2023-11-07. PMID:37935323. |
lingo2 sirna knockdown or egfr inhibitor reversed the effects of delayed recanalization on apoptosis and brain expressions of lingo2, p-egfr, p-src and bcl-2. |
2023-11-07 |
2023-11-20 |
rat |
| Seung-On Lee, Mee-Hyun Lee, Ah-Won Kwak, Jin-Young Lee, Goo Yoon, Sang Hoon Joo, Yung Hyun Choi, Jin Woo Park, Jung-Hyun Shi. Licochalcone H Targets EGFR and AKT to Suppress the Growth of Oxaliplatin -Sensitive and -Resistant Colorectal Cancer Cells. Biomolecules & therapeutics. vol 31. issue 6. 2023-10-30. PMID:37899744. |
taken together lch inhibits the growth of ox-sensitive and ox-resistant crc cells by targeting egfr and akt, and inducing ros generation and er stress-mediated apoptosis. |
2023-10-30 |
2023-11-08 |
Not clear |
| Koh Furugaki, Takaaki Fujimura, Hayato Mizuta, Takuya Yoshimoto, Takashi Asakawa, Yasushi Yoshimura, Shigeki Yoshiur. FGFR blockade inhibits targeted therapy-tolerant persister in basal FGFR1- and FGF2-high cancers with driver oncogenes. NPJ precision oncology. vol 7. issue 1. 2023-10-25. PMID:37880373. |
the combination of fgfr and targeted tkis enhanced cell growth inhibition and apoptosis induction in basal fgfr1- and fgf2-high protein expressing cells with alk-rearranged and epidermal growth factor receptor (egfr)-mutated nsclc, human epidermal growth factor receptor 2 (her2)-amplified breast cancer, or v-raf murine sarcoma viral oncogene homolog b1 (braf)-mutated melanoma by preventing compensatory extracellular signal-regulated kinase (erk) reactivation. |
2023-10-25 |
2023-11-08 |
human |
| Nihan Verimli, S İrem Goralı, Beyza Abisoglu, Cem Levent Altan, Bilgesu Onur Sucu, Ersin Karatas, Ahmet Tulek, Cigdem Bayraktaroglu, Mustafa Caglar Beker, S Sibel Erde. Development of light and pH-dual responsive self-quenching theranostic SPION to make EGFR overexpressing micro tumors glow and destroy. Journal of photochemistry and photobiology. B, Biology. vol 248. 2023-10-20. PMID:37862898. |
anti-egfr scfv targeted spion caused nearly 2-fold higher cell death via apoptosis in high egfr expressing panc-1 cell line. |
2023-10-20 |
2023-11-08 |
Not clear |
| Zhenxing Wang, Lanxin Li, Chunhong Chu, Xiangkai Wei, Qian Liu, Rui Wang, Guoliang Zhang, Guangyao Wu, Ying Wang, Lei An, Xiaodong L. CUDC‑101 is a potential target inhibitor for the EGFR‑overexpression bladder cancer cells. International journal of oncology. vol 63. issue 6. 2023-10-13. PMID:37830158. |
the molecular mechanism underlying its development is complex, but its carcinogenesis has been proposed to occur with cell proliferation and resistance to apoptosis, driven by the signaling activity of abundant egfr and receptor tyrosine‑protein kinase erbb‑2. |
2023-10-13 |
2023-10-15 |
Not clear |
| Cheng-Yao Chiang, Min Zhang, Junrong Huang, Juan Zeng, Chunlan Chen, Dongmei Pan, Heng Yang, Tiantian Zhang, Min Yang, Qiangqiang Han, Zou Wang, Tian Xiao, Yangchao Chen, Yongdong Zou, Feng Yin, Zigang Li, Lizhi Zhu, Duo Zhen. A novel selective ERK1/2 inhibitor, Laxiflorin B, targets EGFR mutation subtypes in non-small-cell lung cancer. Acta pharmacologica Sinica. 2023-10-10. PMID:37816856. |
laxiflorin b induced mitochondria-mediated apoptosis via bad activation in non-small-cell lung cancer (nsclc) cells, especially in egfr mutant subtypes. |
2023-10-10 |
2023-10-15 |
mouse |
| Ravel Ray, Stuti Goel, Hind Al Khashali, Ban Darweesh, Ben Haddad, Caroline Wozniak, Robert Ranzenberger, Jeneen Khalil, Jeffrey Guthrie, Deborah Heyl, Hedeel Guy Evan. Regulation of Soluble E-Cadherin Signaling in Non-Small-Cell Lung Cancer Cells by Nicotine, BDNF, and β-Adrenergic Receptor Ligands. Biomedicines. vol 11. issue 9. 2023-09-28. PMID:37760996. |
in investigating the function of se-cad, we found that immunodepletion of se-cad from the media of a549 cells untreated or treated with bdnf, nicotine, or epinephrine reduced activation of egfr and igf-1r, decreased pi3k and erk1/2 activities, increased p53 activation, decreased cell viability, and increased apoptosis, while no effects were found using h1299 cells under all conditions tested. |
2023-09-28 |
2023-10-07 |
Not clear |
| Junzhe Li, Xiayu Wu, Xiang-Bo Ji, Changhao He, Shijie Xu, Xianhua X. Biphasic function of GSK3β in gefitinib‑resistant NSCLC with or without EGFR mutations. Experimental and therapeutic medicine. vol 26. issue 4. 2023-09-25. PMID:37745038. |
therefore, the present study generated gefitinib-resistant pc-9 (pc-9g) cells, which were revealed to be more resistant to gefitinib-induced reductions in proliferation, migration and invasion, and increases in apoptosis, and had no detectable egfr mutations compared with the control pc-9 cell line. |
2023-09-25 |
2023-10-07 |
Not clear |
| Junzhe Li, Xiayu Wu, Xiang-Bo Ji, Changhao He, Shijie Xu, Xianhua X. Biphasic function of GSK3β in gefitinib‑resistant NSCLC with or without EGFR mutations. Experimental and therapeutic medicine. vol 26. issue 4. 2023-09-25. PMID:37745038. |
furthermore, akt inhibition reduced the proliferation, migration and invasion, and induced the apoptosis of pc-9, pc-9g and h1975 cells, the effects of which were reversed following akt activation; notably, the tumor suppressor function of gsk3β was inconsistent with the tumor promotor role of the akt pathway in pc-9g cells without egfr mutation. |
2023-09-25 |
2023-10-07 |
Not clear |
| Gyan Prakash Rai, Asheesh Shanke. Coevolution-based computational approach to detect resistance mechanism of epidermal growth factor receptor. Biochimica et biophysica acta. Molecular cell research. 2023-09-20. PMID:37730130. |
tyrosine kinase epidermal growth factor receptor (egfr) correlates the neoplastic cell metastasis, angiogenesis, neoplastic incursion, and apoptosis. |
2023-09-20 |
2023-10-07 |
Not clear |
| Fatma Fouad Hagar, Samar H Abbas, Hesham A M Gomaa, Bahaa G M Youssif, Ahmed M Sayed, Dalia Abdelhamid, Mohamed Abdel-Azi. Chalcone/1,3,4-Oxadiazole/Benzimidazole hybrids as novel anti-proliferative agents inducing apoptosis and inhibiting EGFR & BRAFV BMC chemistry. vol 17. issue 1. 2023-09-16. PMID:37716963. |
chalcone/1,3,4-oxadiazole/benzimidazole hybrids as novel anti-proliferative agents inducing apoptosis and inhibiting egfr & brafv one of the most robust global challenges and difficulties in the 21st century is cancer. |
2023-09-16 |
2023-10-07 |
Not clear |
| Qian Zhang, Guoyang Sun, Yuna Huang, Shanshan Cui, Tingshen Li, Lianbo Zhao, Kui Lu, Peng Yu, Yongmin Zhang, Herve Galons, Nassima Oumata, Yuou Ten. Synthesis and mechanism of action of new purine derivatives against triple negative breast cancer. European journal of medicinal chemistry. vol 261. 2023-09-14. PMID:37708799. |
the results in vitro indicated that compounds 3g and 3j can induce mda-mb-231 cells apoptosis, and inhibit its migration and angiogenesis through influencing protein expression such as bcl-2, bax, bcl-xl, p38, mmp2, mmp9, akt and egfr. |
2023-09-14 |
2023-10-07 |
Not clear |